Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for deyo shen
Your search for Deyou Shen retrieved no results
Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma.
Hamad A, DePuccio M, Reames BN, Dave A, Kurien N, Cloyd JM, Shen C, Pawlik TM, Tsung A, McAlearney AS, Ejaz A. Hamad A, et al. J Gastrointest Surg. 2021 Nov;25(11):2889-2901. doi: 10.1007/s11605-021-04984-5. Epub 2021 Mar 25. J Gastrointest Surg. 2021. PMID: 33768427

Older age (OR 0.95, 95%CI 0.94-0.95; p < 0.001), female sex (OR 0.94, 95%CI 0.943-0.97; p < 0.001), African Americans (OR 0.89, 95%CI 0.87-0.91; P < 0.001), and increasing comorbidity burden (Charlson-Deyo score 3: OR 0.52, 95%CI 0.50-0.55; P < 0.001) were asso

…

Older age (OR 0.95, 95%CI 0.94-0.95; p < 0.001), female sex (OR 0.94, 95%CI 0.943-0.97; p < 0.001), African Americans (OR 0.89, 95%CI

…
Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis.
Tamirisa N, Lin H, Shen Y, Shaitelman SF, Karuturi MS, Giordano SH, Babiera GV, Bedrosian I. Tamirisa N, et al. Cancer. 2021 Jul 1;127(13):2196-2203. doi: 10.1002/cncr.33489. Epub 2021 Mar 18. Cancer. 2021. PMID: 33735487 Free PMC article.
METHODS: Women aged 70 years in the National Cancer Database (2010-2014) with Charlson/Deyo comorbidity scores of 2 or 3 who had pathologic tumor (pT1)-pT3/pN0, ER-positive/HER2-negative breast cancer were divided into 2 cohorts: adjuvant ET and no ET. ...
METHODS: Women aged 70 years in the National Cancer Database (2010-2014) with Charlson/Deyo comorbidity scores of 2 or 3 who had path …
Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database.
Buszek SM, Lin HY, Bedrosian I, Tamirisa N, Babiera GV, Shen Y, Shaitelman SF. Buszek SM, et al. Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):795-802. doi: 10.1016/j.ijrobp.2019.07.052. Epub 2019 Aug 1. Int J Radiat Oncol Biol Phys. 2019. PMID: 31377160 Free PMC article.
METHODS AND MATERIALS: We searched the National Cancer Database (2010-2014) for healthy women (aged 70 years, Charlson/Deyo [CD] score 0-1) with T1N0 hormone-receptor-positive, HER-2-negative breast cancer treated with lumpectomy and adjuvant HT or RT. ...
METHODS AND MATERIALS: We searched the National Cancer Database (2010-2014) for healthy women (aged 70 years, Charlson/Deyo [CD] scor …
Perioperative chemotherapy for resectable colorectal liver metastases: Analysis from the Colorectal Operative Liver Metastases International Collaborative (COLOMIC).
Gawdi R, Valenzuela CD, Moaven O, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha C, Russell G, Zarandi N, Dourado J, Shen P. Gawdi R, et al. J Surg Oncol. 2022 Aug;126(2):339-347. doi: 10.1002/jso.26893. Epub 2022 Apr 16. J Surg Oncol. 2022. PMID: 35429409
No differences in median OS were seen between groups on Kaplan-Meier analysis. No significant difference in Charlson-Deyo comorbidity status was seen between groups (p = 0.853), while significant difference was seen in maximum tumor size (p = 0.0023). ...
No differences in median OS were seen between groups on Kaplan-Meier analysis. No significant difference in Charlson-Deyo comorbidity …
The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.
D'Rummo KA, TenNapel MJ, Shen X. D'Rummo KA, et al. Am J Clin Oncol. 2019 Sep;42(9):705-710. doi: 10.1097/COC.0000000000000582. Am J Clin Oncol. 2019. PMID: 31368905
RESULTS: There were 7562 patients included. No differences in age, Charlson-Deyo score, T stage, or node-positive rates were observed between groups. ...
RESULTS: There were 7562 patients included. No differences in age, Charlson-Deyo score, T stage, or node-positive rates were observed …
Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.
Tamirisa N, Lin H, Shen Y, Shaitelman SF, Sri Karuturi M, Giordano SH, Babiera G, Bedrosian I. Tamirisa N, et al. JAMA Oncol. 2020 Oct 1;6(10):1548-1554. doi: 10.1001/jamaoncol.2020.2388. JAMA Oncol. 2020. PMID: 32672820 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients in the US National Cancer Database who were 70 years or older; had a Charlson/Deyo comorbidity score of 2 or 3; had estrogen receptor-positive, ERBB2 (formerly HER2 or HER2/neu)-negative b …
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients in the US National Cancer Database who were 70 years or …
Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.
Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Weiss A, et al. Breast Cancer Res Treat. 2019 Jul;176(2):435-444. doi: 10.1007/s10549-019-05243-7. Epub 2019 Apr 25. Breast Cancer Res Treat. 2019. PMID: 31025270
Patients who underwent SLND alone were older (mean 60.6 years) with more comorbidities (Charlson-Deyo score > 2), smaller primary tumors (mean 2.1 cm), well-differentiated histology, hormone receptor-positive, HER2-negative tumors, without lymphovascular invasion (all P …
Patients who underwent SLND alone were older (mean 60.6 years) with more comorbidities (Charlson-Deyo score > 2), smaller primary …